These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 22731934)
1. Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study. Hartung DM; Middleton L; Svoboda L; McGregor JC CNS Drugs; 2012 Aug; 26(8):707-16. PubMed ID: 22731934 [TBL] [Abstract][Full Text] [Related]
2. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy. Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778 [TBL] [Abstract][Full Text] [Related]
3. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997 [TBL] [Abstract][Full Text] [Related]
4. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. Duh MS; Andermann F; Paradis PE; Weiner J; Manjunath R; Crémieux PY Dis Manag; 2007 Aug; 10(4):216-25. PubMed ID: 17718660 [TBL] [Abstract][Full Text] [Related]
5. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219 [TBL] [Abstract][Full Text] [Related]
6. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy. Das S; Jiang X; Jiang W; Ting TY; Polli JE Epilepsy Behav; 2020 Apr; 105():106936. PubMed ID: 32092462 [TBL] [Abstract][Full Text] [Related]
7. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Makus KG; McCormick J Clin Ther; 2007 Feb; 29(2):334-41. PubMed ID: 17472825 [TBL] [Abstract][Full Text] [Related]
8. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. Privitera MD; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Berg M Lancet Neurol; 2016 Apr; 15(4):365-72. PubMed ID: 26875743 [TBL] [Abstract][Full Text] [Related]
9. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial. Berg M; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Switzer RD; Privitera MD JAMA Neurol; 2017 Aug; 74(8):919-926. PubMed ID: 28654954 [TBL] [Abstract][Full Text] [Related]
10. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. LeLorier J; Duh MS; Paradis PE; Latrémouille-Viau D; Lefebvre P; Manjunath R; Sheehy O Curr Med Res Opin; 2008 Apr; 24(4):1069-81. PubMed ID: 18315941 [TBL] [Abstract][Full Text] [Related]
11. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Andermann F; Duh MS; Gosselin A; Paradis PE Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246 [TBL] [Abstract][Full Text] [Related]
12. Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study. Polard E; Nowak E; Happe A; Biraben A; Oger E; Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1161-9. PubMed ID: 26395769 [TBL] [Abstract][Full Text] [Related]
13. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard. Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987 [TBL] [Abstract][Full Text] [Related]
14. Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study. Kesselheim AS; Bykov K; Gagne JJ; Wang SV; Choudhry NK Neurology; 2016 Oct; 87(17):1796-1801. PubMed ID: 27683844 [TBL] [Abstract][Full Text] [Related]
15. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. Yamada M; Welty TE Ann Pharmacother; 2011 Nov; 45(11):1406-15. PubMed ID: 22028417 [TBL] [Abstract][Full Text] [Related]
16. Association between switching antiepileptic drug products and healthcare utilization: A systematic review. Kwan P; Palmini A Epilepsy Behav; 2017 Aug; 73():166-172. PubMed ID: 28641169 [TBL] [Abstract][Full Text] [Related]
17. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand. Lessing C; Ashton T; Davis P Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492 [TBL] [Abstract][Full Text] [Related]